5th Annual IBDHorizons Midwest Symposium

5th Annual Midwest IBDHorizons Multiplatform Symposium

Course Information
Conference: 1 day – multiplatform meeting for in-person & virtual participation covering the Midwest with an estimated 200 attendees. If an in-person meeting cannot be safely conducted, an exclusively virtual conference platform will be offered.

Intended Audience
This activity was developed for gastroenterologists, advanced nurse practitioners, physician assistants, gastroenterology nurses, pharmacists, and surgeons involved in the care of patients with IBD.

Learning Objectives
At the conclusion of this learning activity, participants will do the following:

  • Analyze the currently available tools to stratify the risk of patients developing complicated IBD vs. mild IBD at diagnosis and the subsequent implications on treatment goals and strategies.
  • Describe the comparative efficacy of the currently available therapies and the rationale for optimal positioning of these agents in IBD today.
  • Outline the goals of IBD care and incorporate the latest concepts, including treat-to-target in IBD clinical practice to optimize patient outcomes.
  • Identify the current endoscopic assessment tools and scoring systems and their practical application in IBD management.
  • Assess the latest evidence regarding the role of therapeutic drug monitoring, proactive and reactive, to optimize response to biologic therapy in patients with IBD.
  • Recognize the various medical and surgical challenges for patients who receive an ileoanal pouch and the latest management recommendations.
  • Review our current understanding of the microbiome in IBD and microbiome manipulation in the management of IBD today.
  • Discuss the newly approved and soon to be approved biologic and non-biologic therapies for IBD, including the risks, efficacy, and special considerations when utilizing these therapies.

Accreditation and Certification
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Annenberg Center for Health Sciences at Eisenhower and IBDHorizons. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Physicians
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 6.5 contact hours may be earned for successful completion of this activity.

Pharmacists

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-22-002-L01-P. This program is designated for up to 6.5 contact hours (0.65 CEUs) of continuing pharmacy education credit.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Disclosure Statement
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in accredited educational activities are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

All individuals in control of the content of continuing education activities provided by the Annenberg Center for Health Sciences at Eisenhower are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All staff at the Annenberg Center for Health Sciences at Eisenhower and IBDHorizons have no relationships to disclose.

IBDHorizons Privacy Policy
https://ibdhorizons.com/privacy-policy/

Annenberg Center for Health Sciences Privacy Policy
Annenberg Center for Health Sciences Privacy Policy: Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at https://annenberg.net/pages/privacyPolicy.php


Hourly Schedule

Saturday, February 12th

7:00 - 7:50
Breakfast
Doors open and buffet breakfast is served
8:00 - 8:15
Welcome & Introduction
Speakers:
Anita Afzali, MD, MPH, MHCM
8:15 - 8:45
Risk Stratification and Prognostic Factors in IBD: Approach to Selecting Initial Therapy
Speakers:
Edward Loftus Jr.
9:00 - 9:45
Updates on Positioning IBD Therapies and Comparative Efficacy
Speakers:
Scott D. Lee MD
9:45 - 10:15
Break - Research Plenary Session
Poster viewing
10:30 -
The Continuing Evolution of Treat to Target Approach in IBD
Speakers:
Ghassan Wahbeh
11:15 -
Understanding and Standardizing Endoscopic Assessment in IBD
Speakers:
Anita Afzali, MD, MPH, MHCM
12:00 -
Lunch
12:45 -
Abstract Awards
13:15 -
Therapeutic Drug Monitoring in IBD Today
Speakers:
Marla Dubinsky
14:00 -
Advances in J-Pouch Management
Speakers:
Feza Remzi, MD
14:45 -
Manipulating the Microbiome in IBD
Speakers:
Jessica Allegretti
3:30 -
Novel Pathways and Upcoming New IBD Therapies
Speakers:
Brian Feagan, MD, MSc
Anita Afzali, MD, MPH, MHCM
Anita Afzali, MD, MPH, MHCM
Professor of Clinical Medicine, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System and Cincinnati Children's Hospital
Dr. Anita Afzali is a Professor of Clinical Medicine in the Division of Digestive Diseases and Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine. Dr. Afzali is also the Associate Chief Medical Officer of the UC Health System and Cincinnati Children's Hospital. She remains an Adjunct Professor of Medicine at OSU. Dr. Afzali holds the Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease. She received her medical degree and then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and also graduated with a Master’s in Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty. While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics at The Ohio State University. Her research interests include clinical outcomes and association of bowel and joint disease, the influence of the metabolic syndrome and impact of race/ethnicity in IBD, as well as pharmacoeconomics, pediatric-to-adult transition, and women of childbearing age with IBD. She is also extensively involved in IBD clinical trials for investigational therapies. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Co-Chair of the Crohn’s & Colitis National Professional Education Committee and Member of the ACG Minority Affairs and Cultural Diversity Committee.
Edward Loftus Jr.
Edward Loftus Jr.
MD, Professor of Medicine
Dr. Edward V. Loftus is a gastroenterologist in Rochester, Minnesota, and is affiliated with Mayo Clinic. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice for more than 20 years. Dr. Loftus specializes in gastroenterology and IBD. He has been the recipient of numerous awards and honors over his years in practice, including but not limited to America's Top Doctors and Teacher of the Year in 2010.
Scott D. Lee MD
Scott D. Lee MD
Associate Professor of Medicine, Director, Clinical Inflammatory Bowel Disease Program at University of Washington Medical Center
Dr. Scott D. Lee is an associate professor of medicine with expertise in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Dr. Lee earned his bachelor’s degree at Pomona College and his M.D. at Jefferson Medical College. He completed his residency in internal medicine at the University of Colorado in Denver. After residency, Dr. Lee completed his gastroenterology fellowship at the University of Washington. After completing his fellowship, he attended the University of Chicago and Cedar-Sinai in Los Angeles as a visiting physician to gain additional training in IBD. Since finishing his fellowship, he has been an attending gastroenterology physician at the University of Washington Medical Center. Currently, his clinical practice is at the Digestive Disease Center at the University of Washington and is dedicated exclusively to providing care to patients with the diagnosis of IBD. His research is focused on inflammatory bowel diseases (IBD) including – new therapies for IBD, improving outcomes in the treatment and long-term management of IBD, evaluation of non-invasive biomarkers to assess disease activity in IBD patients, and the effects of the microbiome on IBD. He has participated in more than 100 clinical trials in IBD and continues to have an active clinical research program. He is a member of the Crohn’s Colitis Foundation of America (CCFA), American Gastroenterology Association, American College of Gastroenterology, and American Society of Gastrointestinal Endoscopy. He is a past chair of Northwest CCFA Chapter Medical Advisory Committee (CMAC) and continues as a current member of the CMAC.
Ghassan Wahbeh
Ghassan Wahbeh
MD, Director of the Inflammatory Bowel Disease Center at Seattle Children’s Hospital
Ghassan Wahbeh, MD, is the director of the Inflammatory Bowel Disease Center at Seattle Children’s Hospital. He is a Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine. Dr. Wahbeh’s clinical focus is in advanced care for children, adolescents, and young adults with Crohn’s Disease and Ulcerative Colitis, including advanced therapeutics and pre and post-surgery IBD management. Dr. Wahbeh’s research interests include advanced management of moderate and severe colitis in the outpatient and inpatient setting, managing complicated Crohn’s disease including fistulizing and stricturing phenotypes, mucosal healing in IBD, navigating surgical options in IBD and novel therapies.
 Dr. Wahbeh is actively involved as teaching faculty in medical student education, resident training, and fellow physician specialty training. He is the honored recipient of the Outstanding Teaching Faculty Award, as well as the Family Choice Award, and the Northwest Crohns & Colitis Foundation service award. He continues to serve as a member of the National Professional Education Committee and the Northwest Medical Advisory Committee of the Crohns and Colitis Foundation of America.
Marla Dubinsky
Marla Dubinsky
Chief of the Division of Pediatric Gastroenterology
Dr. Dubinsky received her medical degree from Queen’s University, Canada. She completed her Pediatric Residency at Alberta Children’s Hospital, Calgary, Canada and her Clinical Fellowship in Gastroenterology and Nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She then completed her Research Fellowship in Inflammatory Bowel Disease at Cedars-Sinai Medical Center in Los Angeles where she then served as the Director of the Pediatric Inflammatory Bowel Disease Center before coming to Mount Sinai as the Chief of the Division of Pediatric Gastroenterology at the Kravis Children’s Hospital at Mount Sinai. Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of early-onset IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally and has published in 120 peer reviewed journals including Lancet, Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and the American Journal of Gastroenterology. She also currently sits on the editorial boards of several leading journals.
Feza Remzi, MD
Feza Remzi, MD
Colorectal Surgeon at NYU Langone, Director of IBD Center, Professor of Surgery at NYU School of Medicine
As a colorectal surgeon at NYU Langone, Dr. Remzi is a foremost expert in the surgical management of Inflammatory Bowel Disease, also known as Crohn’s Disease and Ulcerative Colitis. Dr. Remzi performs pelvic pouch surgery and complex abdominopelvic re-operative surgery, as well as sphincter-saving surgery for rectal cancer, applying minimally invasive techniques to manage colorectal conditions. Dr. Remzi serves as the director of the Inflammatory Bowel Disease Center and is one of the few colorectal surgeons in the world who is specialized in caring for people who are experiencing problems with a prior pelvic pouch, or J-pouch, procedures. He states "I have been humbled and privileged to be able to help my patients for more than 20 years. I treat my patients the way I would treat my own family. I take a team approach to care, so we bring together medical, surgical, and nursing professionals who devote 100 percent of their efforts to giving patients a better chance at life. Many of the people I treat are experiencing complex problems that impact not only their own quality of life but also that of their families. Therefore, I include patients’ family members as a part of the treatment team." As a national and international expert in colorectal surgery, Dr. Remzi has published many articles and book chapters on the surgical management of Inflammatory Bowel Disease, ileal J-pouch surgery, and re-operative abdominopelvic surgery. He is an honored member of the American Surgical Association and is humbled to be one of only a handful of surgeons in the world who is a member of the International Organization For the Study of Inflammatory Bowel Disease.
Jessica Allegretti
Jessica Allegretti
MD, MPH, Associate Director, Crohn's and Colitis Center Assistant Professor, Harvard Medical School
Dr. Jessica Allegretti is an attending gastroenterologist at the BWH Crohn’s and Colitis Center, where she also serves as the center’s Director of Clinical Trials. Dr. Allegretti is extremely dedicated to providing high quality patient care while also conducting important clinical research that will advance the field and provide important opportunities for her patients. In addition to her clinical responsibilities and caring for patients with IBD, Dr. Allegretti is the director of the fecal transplant program for recurrent clostridium difficile at Brigham and Women’s Hospital. She has also participated in multiple clinical trials investigating the use of fecal transplants in other diseases such as inflammatory bowel disease. She is also leading several research projects assessing the treatment of inpatients with ulcerative colitis, and rational de-escalation of infliximab doses in patient with Crohn’s disease. Dr. Allegretti received a grant from the American College of Gastroenterology to further investigate the mechanisms of recurrent clostridium difficile infections and is the lead author of multiple research articles, review papers, and book chapters that have been published in prestigious peer-reviewed journals. She is also an Instructor of Medicine at Harvard Medical School. As an instructor at the medical school, Dr. Allegretti teaches and trains medical students, residents, and research fellows. Dr. Allegretti graduated from Cornell University in Ithaca New York, and The Miller School of Medicine at the University of Miami in Miami, Florida. She was trained in internal medicine at Massachusetts’s General Hospital and completed her gastroenterology fellowship training at Brigham and Women’s Hospital. She later went on to receive a Master’s in Public Health from the Harvard School of Public Health.
Brian Feagan, MD, MSc
Brian Feagan, MD, MSc
Professor of Medicine at the Schulich School of Medicine & Dentistry in London, Ontario, Senior Scientific Director of Alimentiv Inc
Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct, and execution of large-scale randomized controlled trials (RCTs) in Crohn’s disease (CD) and ulcerative colitis (UC), and over the past 30 years, has been Principal Investigator in over 140 multi-center RCTs. His research has been devoted to the development, validation, and optimization of outcome measures to assess the efficacy of novel therapeutics in CD and UC. Dr. Feagan is Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc). Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada. His postdoctoral training included a residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC), and the European Crohn’s & Colitis Organization (ECCO). He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA) and the Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 200 articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials (now Alimentiv, Inc.).

Date

Feb 12 2022

Time

8:00 am - 4:00 pm

Location

Hilton Columbus Downtown
401 N High St, Columbus, OH 43215

Speakers

  • Anita Afzali, MD, MPH, MHCM
    Anita Afzali, MD, MPH, MHCM
    Professor of Clinical Medicine, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System and Cincinnati Children's Hospital

    Dr. Anita Afzali is a Professor of Clinical Medicine in the Division of Digestive Diseases and Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine. Dr. Afzali is also the Associate Chief Medical Officer of the UC Health System and Cincinnati Children’s Hospital.

    She remains an Adjunct Professor of Medicine at OSU.
    Dr. Afzali holds the Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease. She received her medical degree and then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and also graduated with a Master’s in Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty. While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics at The Ohio State University.
    Her research interests include clinical outcomes and association of bowel and joint disease, the influence of the metabolic syndrome and impact of race/ethnicity in IBD, as well as pharmacoeconomics, pediatric-to-adult transition, and women of childbearing age with IBD. She is also extensively involved in IBD clinical trials for investigational therapies. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Co-Chair of the Crohn’s & Colitis National Professional Education Committee and Member of the ACG Minority Affairs and Cultural Diversity Committee.

  • Brian Feagan, MD, MSc
    Brian Feagan, MD, MSc
    Professor of Medicine at the Schulich School of Medicine & Dentistry in London, Ontario, Senior Scientific Director of Alimentiv Inc

    Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct, and execution of large-scale randomized controlled trials (RCTs) in Crohn’s disease (CD) and ulcerative colitis (UC), and over the past 30 years, has been Principal Investigator in over 140 multi-center RCTs. His research has been devoted to the development, validation, and optimization of outcome measures to assess the efficacy of novel therapeutics in CD and UC. Dr. Feagan is Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc).

    Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada. His postdoctoral training included a residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC), and the European Crohn’s & Colitis Organization (ECCO). He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA) and the Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 200 articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials (now Alimentiv, Inc.).

  • Edward Loftus Jr.
    Edward Loftus Jr.
    MD, Professor of Medicine

    Dr. Edward V. Loftus is a gastroenterologist in Rochester, Minnesota, and is affiliated with Mayo Clinic. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice for more than 20 years.
    Dr. Loftus specializes in gastroenterology and IBD. He has been the recipient of numerous awards and honors over his years in practice, including but not limited to America’s Top Doctors and Teacher of the Year in 2010.

  • Feza Remzi, MD
    Feza Remzi, MD
    Colorectal Surgeon at NYU Langone, Director of IBD Center, Professor of Surgery at NYU School of Medicine

    As a colorectal surgeon at NYU Langone, Dr. Remzi is a foremost expert in the surgical management of Inflammatory Bowel Disease, also known as Crohn’s Disease and Ulcerative Colitis. Dr. Remzi performs pelvic pouch surgery and complex abdominopelvic re-operative surgery, as well as sphincter-saving surgery for rectal cancer, applying minimally invasive techniques to manage colorectal conditions.
    Dr. Remzi serves as the director of the Inflammatory Bowel Disease Center and is one of the few colorectal surgeons in the world who is specialized in caring for people who are experiencing problems with a prior pelvic pouch, or J-pouch, procedures. He states “I have been humbled and privileged to be able to help my patients for more than 20 years. I treat my patients the way I would treat my own family. I take a team approach to care, so we bring together medical, surgical, and nursing professionals who devote 100 percent of their efforts to giving patients a better chance at life. Many of the people I treat are experiencing complex problems that impact not only their own quality of life but also that of their families. Therefore, I include patients’ family members as a part of the treatment team.”
    As a national and international expert in colorectal surgery, Dr. Remzi has published many articles and book chapters on the surgical management of Inflammatory Bowel Disease, ileal J-pouch surgery, and re-operative abdominopelvic surgery. He is an honored member of the American Surgical Association and is humbled to be one of only a handful of surgeons in the world who is a member of the International Organization For the Study of Inflammatory Bowel Disease.

  • Ghassan Wahbeh
    Ghassan Wahbeh
    MD, Director of the Inflammatory Bowel Disease Center at Seattle Children’s Hospital

    Ghassan Wahbeh, MD, is the director of the Inflammatory Bowel Disease Center at Seattle Children’s Hospital. He is a Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine. Dr. Wahbeh’s clinical focus is in advanced care for children, adolescents, and young adults with Crohn’s Disease and Ulcerative Colitis, including advanced therapeutics and pre and post-surgery IBD management.

    Dr. Wahbeh’s research interests include advanced management of moderate and severe colitis in the outpatient and inpatient setting, managing complicated Crohn’s disease including fistulizing and stricturing phenotypes, mucosal healing in IBD, navigating surgical options in IBD and novel therapies.
 Dr. Wahbeh is actively involved as teaching faculty in medical student education, resident training, and fellow physician specialty training. He is the honored recipient of the Outstanding Teaching Faculty Award, as well as the Family Choice Award, and the Northwest Crohns & Colitis Foundation service award. He continues to serve as a member of the National Professional Education Committee and the Northwest Medical Advisory Committee of the Crohns and Colitis Foundation of America.

  • Jessica Allegretti
    Jessica Allegretti
    MD, MPH, Associate Director, Crohn's and Colitis Center Assistant Professor, Harvard Medical School

    Dr. Jessica Allegretti is an attending gastroenterologist at the BWH Crohn’s and Colitis Center, where she also serves as the center’s Director of Clinical Trials. Dr. Allegretti is extremely dedicated to providing high quality patient care while also conducting important clinical research that will advance the field and provide important opportunities for her patients.

    In addition to her clinical responsibilities and caring for patients with IBD, Dr. Allegretti is the director of the fecal transplant program for recurrent clostridium difficile at Brigham and Women’s Hospital. She has also participated in multiple clinical trials investigating the use of fecal transplants in other diseases such as inflammatory bowel disease. She is also leading several research projects assessing the treatment of inpatients with ulcerative colitis, and rational de-escalation of infliximab doses in patient with Crohn’s disease.

    Dr. Allegretti received a grant from the American College of Gastroenterology to further investigate the mechanisms of recurrent clostridium difficile infections and is the lead author of multiple research articles, review papers, and book chapters that have been published in prestigious peer-reviewed journals.

    She is also an Instructor of Medicine at Harvard Medical School. As an instructor at the medical school, Dr. Allegretti teaches and trains medical students, residents, and research fellows.

    Dr. Allegretti graduated from Cornell University in Ithaca New York, and The Miller School of Medicine at the University of Miami in Miami, Florida. She was trained in internal medicine at Massachusetts’s General Hospital and completed her gastroenterology fellowship training at Brigham and Women’s Hospital. She later went on to receive a Master’s in Public Health from the Harvard School of Public Health.

  • Marla Dubinsky
    Marla Dubinsky
    Chief of the Division of Pediatric Gastroenterology

    Dr. Dubinsky received her medical degree from Queen’s University, Canada. She completed her Pediatric Residency at Alberta Children’s Hospital, Calgary, Canada and her Clinical Fellowship in Gastroenterology and Nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She then completed her Research Fellowship in Inflammatory Bowel Disease at Cedars-Sinai Medical Center in Los Angeles where she then served as the Director of the Pediatric Inflammatory Bowel Disease Center before coming to Mount Sinai as the Chief of the Division of Pediatric Gastroenterology at the Kravis Children’s Hospital at Mount Sinai. Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of early-onset IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally and has published in 120 peer reviewed journals including Lancet, Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and the American Journal of Gastroenterology. She also currently sits on the editorial boards of several leading journals.

  • Scott D. Lee MD
    Scott D. Lee MD
    Associate Professor of Medicine, Director, Clinical Inflammatory Bowel Disease Program at University of Washington Medical Center

    Dr. Scott D. Lee is an associate professor of medicine with expertise in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Dr. Lee earned his bachelor’s degree at Pomona College and his M.D. at Jefferson Medical College. He completed his residency in internal medicine at the University of Colorado in Denver. After residency, Dr. Lee completed his gastroenterology fellowship at the University of Washington. After completing his fellowship, he attended the University of Chicago and Cedar-Sinai in Los Angeles as a visiting physician to gain additional training in IBD. Since finishing his fellowship, he has been an attending gastroenterology physician at the University of Washington Medical Center. Currently, his clinical practice is at the Digestive Disease Center at the University of Washington and is dedicated exclusively to providing care to patients with the diagnosis of IBD. His research is focused on inflammatory bowel diseases (IBD) including – new therapies for IBD, improving outcomes in the treatment and long-term management of IBD, evaluation of non-invasive biomarkers to assess disease activity in IBD patients, and the effects of the microbiome on IBD. He has participated in more than 100 clinical trials in IBD and continues to have an active clinical research program. He is a member of the Crohn’s Colitis Foundation of America (CCFA), American Gastroenterology Association, American College of Gastroenterology, and American Society of Gastrointestinal Endoscopy. He is a past chair of Northwest CCFA Chapter Medical Advisory Committee (CMAC) and continues as a current member of the CMAC.

QR Code

Hourly Schedule

Saturday, February 12th

7:00 - 7:50
Breakfast
Doors open and buffet breakfast is served
8:00 - 8:15
Welcome & Introduction
Speakers:
Anita Afzali, MD, MPH, MHCM
8:15 - 8:45
Risk Stratification and Prognostic Factors in IBD: Approach to Selecting Initial Therapy
Speakers:
Edward Loftus Jr.
9:00 - 9:45
Updates on Positioning IBD Therapies and Comparative Efficacy
Speakers:
Scott D. Lee MD
9:45 - 10:15
Break - Research Plenary Session
Poster viewing
10:30 -
The Continuing Evolution of Treat to Target Approach in IBD
Speakers:
Ghassan Wahbeh
11:15 -
Understanding and Standardizing Endoscopic Assessment in IBD
Speakers:
Anita Afzali, MD, MPH, MHCM
12:00 -
Lunch
12:45 -
Abstract Awards
13:15 -
Therapeutic Drug Monitoring in IBD Today
Speakers:
Marla Dubinsky
14:00 -
Advances in J-Pouch Management
Speakers:
Feza Remzi, MD
14:45 -
Manipulating the Microbiome in IBD
Speakers:
Jessica Allegretti
3:30 -
Novel Pathways and Upcoming New IBD Therapies
Speakers:
Brian Feagan, MD, MSc
Anita Afzali, MD, MPH, MHCM
Anita Afzali, MD, MPH, MHCM
Professor of Clinical Medicine, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System and Cincinnati Children's Hospital
Dr. Anita Afzali is a Professor of Clinical Medicine in the Division of Digestive Diseases and Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine. Dr. Afzali is also the Associate Chief Medical Officer of the UC Health System and Cincinnati Children's Hospital. She remains an Adjunct Professor of Medicine at OSU. Dr. Afzali holds the Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease. She received her medical degree and then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and also graduated with a Master’s in Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty. While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics at The Ohio State University. Her research interests include clinical outcomes and association of bowel and joint disease, the influence of the metabolic syndrome and impact of race/ethnicity in IBD, as well as pharmacoeconomics, pediatric-to-adult transition, and women of childbearing age with IBD. She is also extensively involved in IBD clinical trials for investigational therapies. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Co-Chair of the Crohn’s & Colitis National Professional Education Committee and Member of the ACG Minority Affairs and Cultural Diversity Committee.
Edward Loftus Jr.
Edward Loftus Jr.
MD, Professor of Medicine
Dr. Edward V. Loftus is a gastroenterologist in Rochester, Minnesota, and is affiliated with Mayo Clinic. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice for more than 20 years. Dr. Loftus specializes in gastroenterology and IBD. He has been the recipient of numerous awards and honors over his years in practice, including but not limited to America's Top Doctors and Teacher of the Year in 2010.
Scott D. Lee MD
Scott D. Lee MD
Associate Professor of Medicine, Director, Clinical Inflammatory Bowel Disease Program at University of Washington Medical Center
Dr. Scott D. Lee is an associate professor of medicine with expertise in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Dr. Lee earned his bachelor’s degree at Pomona College and his M.D. at Jefferson Medical College. He completed his residency in internal medicine at the University of Colorado in Denver. After residency, Dr. Lee completed his gastroenterology fellowship at the University of Washington. After completing his fellowship, he attended the University of Chicago and Cedar-Sinai in Los Angeles as a visiting physician to gain additional training in IBD. Since finishing his fellowship, he has been an attending gastroenterology physician at the University of Washington Medical Center. Currently, his clinical practice is at the Digestive Disease Center at the University of Washington and is dedicated exclusively to providing care to patients with the diagnosis of IBD. His research is focused on inflammatory bowel diseases (IBD) including – new therapies for IBD, improving outcomes in the treatment and long-term management of IBD, evaluation of non-invasive biomarkers to assess disease activity in IBD patients, and the effects of the microbiome on IBD. He has participated in more than 100 clinical trials in IBD and continues to have an active clinical research program. He is a member of the Crohn’s Colitis Foundation of America (CCFA), American Gastroenterology Association, American College of Gastroenterology, and American Society of Gastrointestinal Endoscopy. He is a past chair of Northwest CCFA Chapter Medical Advisory Committee (CMAC) and continues as a current member of the CMAC.
Ghassan Wahbeh
Ghassan Wahbeh
MD, Director of the Inflammatory Bowel Disease Center at Seattle Children’s Hospital
Ghassan Wahbeh, MD, is the director of the Inflammatory Bowel Disease Center at Seattle Children’s Hospital. He is a Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine. Dr. Wahbeh’s clinical focus is in advanced care for children, adolescents, and young adults with Crohn’s Disease and Ulcerative Colitis, including advanced therapeutics and pre and post-surgery IBD management. Dr. Wahbeh’s research interests include advanced management of moderate and severe colitis in the outpatient and inpatient setting, managing complicated Crohn’s disease including fistulizing and stricturing phenotypes, mucosal healing in IBD, navigating surgical options in IBD and novel therapies.
 Dr. Wahbeh is actively involved as teaching faculty in medical student education, resident training, and fellow physician specialty training. He is the honored recipient of the Outstanding Teaching Faculty Award, as well as the Family Choice Award, and the Northwest Crohns & Colitis Foundation service award. He continues to serve as a member of the National Professional Education Committee and the Northwest Medical Advisory Committee of the Crohns and Colitis Foundation of America.
Marla Dubinsky
Marla Dubinsky
Chief of the Division of Pediatric Gastroenterology
Dr. Dubinsky received her medical degree from Queen’s University, Canada. She completed her Pediatric Residency at Alberta Children’s Hospital, Calgary, Canada and her Clinical Fellowship in Gastroenterology and Nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She then completed her Research Fellowship in Inflammatory Bowel Disease at Cedars-Sinai Medical Center in Los Angeles where she then served as the Director of the Pediatric Inflammatory Bowel Disease Center before coming to Mount Sinai as the Chief of the Division of Pediatric Gastroenterology at the Kravis Children’s Hospital at Mount Sinai. Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of early-onset IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally and has published in 120 peer reviewed journals including Lancet, Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and the American Journal of Gastroenterology. She also currently sits on the editorial boards of several leading journals.
Feza Remzi, MD
Feza Remzi, MD
Colorectal Surgeon at NYU Langone, Director of IBD Center, Professor of Surgery at NYU School of Medicine
As a colorectal surgeon at NYU Langone, Dr. Remzi is a foremost expert in the surgical management of Inflammatory Bowel Disease, also known as Crohn’s Disease and Ulcerative Colitis. Dr. Remzi performs pelvic pouch surgery and complex abdominopelvic re-operative surgery, as well as sphincter-saving surgery for rectal cancer, applying minimally invasive techniques to manage colorectal conditions. Dr. Remzi serves as the director of the Inflammatory Bowel Disease Center and is one of the few colorectal surgeons in the world who is specialized in caring for people who are experiencing problems with a prior pelvic pouch, or J-pouch, procedures. He states "I have been humbled and privileged to be able to help my patients for more than 20 years. I treat my patients the way I would treat my own family. I take a team approach to care, so we bring together medical, surgical, and nursing professionals who devote 100 percent of their efforts to giving patients a better chance at life. Many of the people I treat are experiencing complex problems that impact not only their own quality of life but also that of their families. Therefore, I include patients’ family members as a part of the treatment team." As a national and international expert in colorectal surgery, Dr. Remzi has published many articles and book chapters on the surgical management of Inflammatory Bowel Disease, ileal J-pouch surgery, and re-operative abdominopelvic surgery. He is an honored member of the American Surgical Association and is humbled to be one of only a handful of surgeons in the world who is a member of the International Organization For the Study of Inflammatory Bowel Disease.
Jessica Allegretti
Jessica Allegretti
MD, MPH, Associate Director, Crohn's and Colitis Center Assistant Professor, Harvard Medical School
Dr. Jessica Allegretti is an attending gastroenterologist at the BWH Crohn’s and Colitis Center, where she also serves as the center’s Director of Clinical Trials. Dr. Allegretti is extremely dedicated to providing high quality patient care while also conducting important clinical research that will advance the field and provide important opportunities for her patients. In addition to her clinical responsibilities and caring for patients with IBD, Dr. Allegretti is the director of the fecal transplant program for recurrent clostridium difficile at Brigham and Women’s Hospital. She has also participated in multiple clinical trials investigating the use of fecal transplants in other diseases such as inflammatory bowel disease. She is also leading several research projects assessing the treatment of inpatients with ulcerative colitis, and rational de-escalation of infliximab doses in patient with Crohn’s disease. Dr. Allegretti received a grant from the American College of Gastroenterology to further investigate the mechanisms of recurrent clostridium difficile infections and is the lead author of multiple research articles, review papers, and book chapters that have been published in prestigious peer-reviewed journals. She is also an Instructor of Medicine at Harvard Medical School. As an instructor at the medical school, Dr. Allegretti teaches and trains medical students, residents, and research fellows. Dr. Allegretti graduated from Cornell University in Ithaca New York, and The Miller School of Medicine at the University of Miami in Miami, Florida. She was trained in internal medicine at Massachusetts’s General Hospital and completed her gastroenterology fellowship training at Brigham and Women’s Hospital. She later went on to receive a Master’s in Public Health from the Harvard School of Public Health.
Brian Feagan, MD, MSc
Brian Feagan, MD, MSc
Professor of Medicine at the Schulich School of Medicine & Dentistry in London, Ontario, Senior Scientific Director of Alimentiv Inc
Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct, and execution of large-scale randomized controlled trials (RCTs) in Crohn’s disease (CD) and ulcerative colitis (UC), and over the past 30 years, has been Principal Investigator in over 140 multi-center RCTs. His research has been devoted to the development, validation, and optimization of outcome measures to assess the efficacy of novel therapeutics in CD and UC. Dr. Feagan is Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc). Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada. His postdoctoral training included a residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC), and the European Crohn’s & Colitis Organization (ECCO). He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA) and the Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 200 articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials (now Alimentiv, Inc.).
QR Code

8 Responses

  1. Is this presentation available online? I live in Ohio. If so, please advise how to register for the virtual event.
    Thank you.

  2. I have registered for this event but would like to attend it virtually if possible. Please let me know if that is an option.

Leave a Reply

Your email address will not be published.

Thank you!

Success! We have received your activity evaluation and application for credit.

How do I receive my credit?

You already did it by submitting this evaluation within two weeks from the event date.

When can I expect my credit?

Please allow 4-6 weeks from the date of the event for processing.

Who will I hear from?

The Annenberg Center for Health Sciences at Eisenhower processes certificates and will be the one to email you.

Will they email my certificate directly?

No, they will email you instructions to download the certificate from their site.

Your submission has been received!

We appreciate your submission into the Research Plenary Session at the 7th Annual IBDHorizons Pacific Northwest Symposium. The program committee looks forward to reviewing each submission carefully.  The team will notify about decisions by February 28, 2022 via email. Please check that you received a confirmation email.

For the winners, we are excited to hear your abstracts presented during the 7th Pacific Northwest Symposium on Saturday, March 5, 2022 at the Hyatt Regency Seattle. Further details will be provided by email. Thank you again and don’t forget to register!

Your submission has been received!

We appreciate your submission into the Research Plenary Session at the 5th Annual IBDHorizons Midwest Symposium. The program committee looks forward to reviewing each submission carefully.  The team will notify about decisions by January 20, 2022 via email. Please check that you received a confirmation email.

For the winners, we are excited to hear your abstracts presented during the 5th Midwest Symposium on Saturday, February 12, 2022 at the Hilton Columbus Downtown. Further details will be provided by email. Thank you again and don’t forget to register!